Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome

Robertino Dilena, Eleonora Mauri, Eleonora Aronica, Pia Bernasconi, Cristina Bana, Cristina Cappelletti, Giorgio Carrabba, Stefano Ferrero, Roberto Giorda, Sophie Guez, Stefano Scalia Catenacci, Fabio Triulzi, Sergio Barbieri, Edoardo Calderini, Annamaria Vezzani

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Febrile infection–related epilepsy syndrome (FIRES) is a severe epileptic encephalopathy with presumed inflammatory origin and lacking effective treatments. Anakinra is the human recombinant interleukin 1 receptor antagonist clinically used in autoinflammatory or autoimmune conditions. We report a case of FIRES for which the spatial and temporal match between electroencephalography (EEG) and magnetic resonance imaging (MRI) focal alterations provides support for the detrimental synergic interplay between seizures and inflammation that may evolve to permanent focal lesions and progressive brain atrophy in weeks to months. Brain biopsy showed aspects of chronic neuroinflammation with scarce parenchymal lymphocytes. We report the novel evidence that anakinra reduces the relapse of highly recurrent refractory seizures at 1.5 years after FIRES onset. Our evidence, together with previously reported therapeutic effects of anakinra administered since the first days of disease onset, support the hypothesis that interleukin 1β and inflammation-related factors play a crucial role in seizure recurrence in both the acute and chronic stages of the disease.

Original languageEnglish
Pages (from-to)344-350
Number of pages7
JournalEpilepsia Open
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Therapeutic Uses
Epilepsy
Seizures
Fever
Inflammation
Recurrence
Interleukin-1 Receptors
Brain
Brain Diseases
Interleukin-1
Atrophy
Electroencephalography
Chronic Disease
Magnetic Resonance Imaging
Lymphocytes
Biopsy
Therapeutics

Keywords

  • epileptic encephalopathy
  • febrile infection–related epilepsy syndrome
  • IL-1β
  • neuroinflammation

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome. / Dilena, Robertino; Mauri, Eleonora; Aronica, Eleonora; Bernasconi, Pia; Bana, Cristina; Cappelletti, Cristina; Carrabba, Giorgio; Ferrero, Stefano; Giorda, Roberto; Guez, Sophie; Scalia Catenacci, Stefano; Triulzi, Fabio; Barbieri, Sergio; Calderini, Edoardo; Vezzani, Annamaria.

In: Epilepsia Open, Vol. 4, No. 2, 01.06.2019, p. 344-350.

Research output: Contribution to journalArticle

@article{17c5d35a163a46588e0b3f05d2eceadc,
title = "Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome",
abstract = "Febrile infection–related epilepsy syndrome (FIRES) is a severe epileptic encephalopathy with presumed inflammatory origin and lacking effective treatments. Anakinra is the human recombinant interleukin 1 receptor antagonist clinically used in autoinflammatory or autoimmune conditions. We report a case of FIRES for which the spatial and temporal match between electroencephalography (EEG) and magnetic resonance imaging (MRI) focal alterations provides support for the detrimental synergic interplay between seizures and inflammation that may evolve to permanent focal lesions and progressive brain atrophy in weeks to months. Brain biopsy showed aspects of chronic neuroinflammation with scarce parenchymal lymphocytes. We report the novel evidence that anakinra reduces the relapse of highly recurrent refractory seizures at 1.5 years after FIRES onset. Our evidence, together with previously reported therapeutic effects of anakinra administered since the first days of disease onset, support the hypothesis that interleukin 1β and inflammation-related factors play a crucial role in seizure recurrence in both the acute and chronic stages of the disease.",
keywords = "epileptic encephalopathy, febrile infection–related epilepsy syndrome, IL-1β, neuroinflammation",
author = "Robertino Dilena and Eleonora Mauri and Eleonora Aronica and Pia Bernasconi and Cristina Bana and Cristina Cappelletti and Giorgio Carrabba and Stefano Ferrero and Roberto Giorda and Sophie Guez and {Scalia Catenacci}, Stefano and Fabio Triulzi and Sergio Barbieri and Edoardo Calderini and Annamaria Vezzani",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/epi4.12317",
language = "English",
volume = "4",
pages = "344--350",
journal = "Epilepsia Open",
issn = "2470-9239",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome

AU - Dilena, Robertino

AU - Mauri, Eleonora

AU - Aronica, Eleonora

AU - Bernasconi, Pia

AU - Bana, Cristina

AU - Cappelletti, Cristina

AU - Carrabba, Giorgio

AU - Ferrero, Stefano

AU - Giorda, Roberto

AU - Guez, Sophie

AU - Scalia Catenacci, Stefano

AU - Triulzi, Fabio

AU - Barbieri, Sergio

AU - Calderini, Edoardo

AU - Vezzani, Annamaria

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Febrile infection–related epilepsy syndrome (FIRES) is a severe epileptic encephalopathy with presumed inflammatory origin and lacking effective treatments. Anakinra is the human recombinant interleukin 1 receptor antagonist clinically used in autoinflammatory or autoimmune conditions. We report a case of FIRES for which the spatial and temporal match between electroencephalography (EEG) and magnetic resonance imaging (MRI) focal alterations provides support for the detrimental synergic interplay between seizures and inflammation that may evolve to permanent focal lesions and progressive brain atrophy in weeks to months. Brain biopsy showed aspects of chronic neuroinflammation with scarce parenchymal lymphocytes. We report the novel evidence that anakinra reduces the relapse of highly recurrent refractory seizures at 1.5 years after FIRES onset. Our evidence, together with previously reported therapeutic effects of anakinra administered since the first days of disease onset, support the hypothesis that interleukin 1β and inflammation-related factors play a crucial role in seizure recurrence in both the acute and chronic stages of the disease.

AB - Febrile infection–related epilepsy syndrome (FIRES) is a severe epileptic encephalopathy with presumed inflammatory origin and lacking effective treatments. Anakinra is the human recombinant interleukin 1 receptor antagonist clinically used in autoinflammatory or autoimmune conditions. We report a case of FIRES for which the spatial and temporal match between electroencephalography (EEG) and magnetic resonance imaging (MRI) focal alterations provides support for the detrimental synergic interplay between seizures and inflammation that may evolve to permanent focal lesions and progressive brain atrophy in weeks to months. Brain biopsy showed aspects of chronic neuroinflammation with scarce parenchymal lymphocytes. We report the novel evidence that anakinra reduces the relapse of highly recurrent refractory seizures at 1.5 years after FIRES onset. Our evidence, together with previously reported therapeutic effects of anakinra administered since the first days of disease onset, support the hypothesis that interleukin 1β and inflammation-related factors play a crucial role in seizure recurrence in both the acute and chronic stages of the disease.

KW - epileptic encephalopathy

KW - febrile infection–related epilepsy syndrome

KW - IL-1β

KW - neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=85066431780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066431780&partnerID=8YFLogxK

U2 - 10.1002/epi4.12317

DO - 10.1002/epi4.12317

M3 - Article

AN - SCOPUS:85066431780

VL - 4

SP - 344

EP - 350

JO - Epilepsia Open

JF - Epilepsia Open

SN - 2470-9239

IS - 2

ER -